Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines

abstract

Noonan syndrome (NS) is a common, clinically and genetically heterogeneous condition characterized by distinctive facial features, short stature, chest deformity, congenital heart disease, and other comorbidities. Gene mutations identified in individuals with the NS phenotype are involved in the Ras/MAPK (mitogen-activated protein kinase) signal transduction pathway and currently explain ~61% of NS cases. Thus, NS frequently remains a clinical diagnosis. Because of the variability in presentation and the need for multidisciplinary care, it is essential that the condition be identified and managed comprehensively. The Noonan Syndrome Support Group (NSSG) is a nonprofit organization committed to providing support, current information, and understanding to those affected by NS. The NSSG convened a conference of health care providers, all involved in various aspects of NS, to develop these guidelines for use by pediatricians in the diagnosis and management of individuals with NS and to provide updated genetic findings.

Pediatrics 2010;126:746–759

AUTHORS: Alicia A. Romano, MD,a Judith E. Allanson, MD,b Jovanna Dahlgren, MD,c Bruce D. Gelb, MD,d Bryan Hall, MD,e Mary Ella Pierpont, MD,f,g Amy E. Roberts, MD,h Wanda Robinson,i Clifford M. Takemoto, MD,j and Jacqueline A. Noonan, MDk

aDivision of Pediatric Endocrinology, Department of Pediatrics, New York Medical College, Valhalla, New York; bDepartment of Genetics, Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada; cGöteborg Pediatric Growth Research Center, Institute for Clinical Sciences, Queen Silva Children’s Hospital, Göteborg, Sweden; dCenter for Molecular Cardiology and Department of Pediatrics, Mount Sinai School of Medicine, New York, New York; eDepartment of Pediatrics, University of Kentucky Medical Center, Lexington, Kentucky; fDivision of Genetics, Children’s Hospital and Clinics of Minnesota, Minneapolis, Minnesota; gDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota; hDepartment of Cardiology and Division of Genetics, Children’s Hospital Boston, Boston, Massachusetts; iNoonan Syndrome Support Group, Baltimore, Maryland; jDivision of Pediatric Hematology, Johns Hopkins Hospital, Baltimore, Maryland; and kDivision of Pediatric Cardiology, University of Kentucky Medical Center, Lexington, Kentucky

KEY WORDS
Noonan syndrome, PTPN11, SOS1, BRAF, KRAS, NRAS, RAF1, SHOC2, Ras/MAPK signal transduction, congenital heart disease, short stature

ABBREVIATIONS
NS—Noonan syndrome
CFC—cardiofaciocutaneous
MAPK—mitogen-activated protein kinase
LEOPARD—lentigines, electrocardiographic anomalies, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, and deafness
PTPN11—protein tyrosine phosphatase non–receptor type 11 gene
PVSD—pulmonary valve stenosis
GH—growth hormone
ASD—atrial septal defect
HCM—hypertrophic cardiomyopathy
MPD—myeloproliferative disorder

www.pediatrics.org/cgi/doi/10.1542/peds.2009-3207
doi:10.1542/peds.2009-3207
Accepted for publication Jul 23, 2010
Address correspondence to Alicia A. Romano, MD, Department of Pediatrics, Munger Pavilion, Room 123, New York Medical College, Valhalla, NY 10595. E-mail: alicia.romano@mac.com

(Continued on last page)
Noonan syndrome (NS) is a relatively common congenital genetic disorder with an estimated prevalence of 1 in 1000 to 1 in 2500 live births. Characteristic findings include distinctive facial features, short stature, chest deformity, and congenital heart disease. It is an autosomal dominant disorder with complete penetrance but variable expressivity. Until recently, diagnosis was based solely on clinical findings, but genetic mutations are identifiable in ~61% of the patients. Because of the difficulty in establishing a diagnosis of NS, the Noonan Syndrome Support Group coordinated a meeting of health care providers with expertise in various aspects of the disorder with the aim of developing guidelines for its diagnosis and management. This report is the result of those efforts and is intended to provide the pediatrician with key clinical features of NS, to provide an update of currently unclustered aspects of the disorder with the aim of developing guidelines for its diagnosis and management. This report is the result of those efforts and is intended to provide the pediatrician with key clinical features of NS, to provide an update of currently unclustered genetic causes, and to present management recommendations (Table 1).

A description of the meeting methodology is provided in Supplemental Information.

**HISTORY OF NS**

In 1962, Jacqueline Noonan, a pediatric cardiologist, identified 9 patients whose faces were remarkably similar and who, in addition, had short stature, significant chest deformities, and pulmonary stenosis. In 1968 Dr Noonan published a case series with these 9 plus an additional 10 patients. The eponym “Noonan syndrome” was adopted in recognition of Dr Noonan, because she was the first to indicate that this condition occurred in both genders, was associated with normal chromosomes, included congenital heart defects, and could be familial.

**CLINICAL DESCRIPTION AND DIFFERENTIAL DIAGNOSIS**

Facial and musculoskeletal features most often lead to the diagnosis of NS. The facial appearance is most characteristic in infancy (Fig 1) and early-to-middle childhood and becomes more subtle in adulthood (Fig 1B). In the newborn infant with NS, the head is large with a small face tucked beneath a large cranium, a tall forehead, and narrowing at the temples. The eyes are wide-spaced and prominent with epicanthal folds, ptosis, and horizontal or down-slanting palpebral fissures (95%). There may be telecanthus as well as hypertelorism. The nose is short and broad with a depressed root and full tip. The ears are low-set, are posteriorly rotated, and have an oval shape and thickening of the helix (90%). The upper lip is distinctive with a deeply grooved philtrum with high, wide peaks to the vermilion of the upper lip (95%), and full lips. Generally, the neck is short with excess skin and a low posterior hairline (55%). In middle-to-late childhood, facial appearance often lacks expression and resembles the face of an individual with a myopathy. By adolescence, face shape is an inverted triangle, wide at the forehead and tapered to a pointed chin. Eyes are less prominent. Features are sharper. There is a narrow nasal root with a thin bridge. The neck is longer, accentuating skin webbing or prominence of the trapezius muscle. The adult face may be quite unremarkable, although the same individual may have had more obvious features as an infant. Some adults, however, have typical features including ptosis, wide-spaced eyes, low-set ears with posterior rotation and thickened helix, and broad or webbed neck. In the older adult, nasolabial folds are more prominent than one would expect for that person’s age, and the skin appears transparent and thin.

Hair may be wispy in the toddler, whereas it is often curly or wooly in the older child and adolescent. Regardless of age, eyes are frequently pale blue or blue-green and much lighter in color than expected for family background. A characteristic pectus deformity of the chest with pectus carinatum superiorly and pectus excavatum inferiorly is seen in most individuals. Also, nipples are wide-spaced and low-set, and rounded shoulders are common. Scoliosis is reported in 10% to 15%. Other less common spinal abnormalities include kyphosis, spina bifida, vertebral and rib abnormalities, and genu valgum. Talipes equinovarus is described in 10% to 15%, other joint contractures in 4%, radio-ulnar synostosis in 2%, and cervical spine fusion in 2%. Abnormal forearm carrying angles (cubitus valgus) are found in more than half the males (10–11°) and females (14–15°). Hyperextensibility is common.

Because of differences in prognosis, recurrence concerns, and treatment, accurate diagnosis is essential. There are several disorders with significant phenotypic overlap with NS, such as Turner syndrome (Table 2). For many years, before our understanding of their underlying genetic causes, cardiofaciocutaneous (CFC) syndrome and Costello syndrome were often confused for NS, particularly in the newborn period. Therefore, it was not surprising that they, like NS, were found to be caused by mutations in genes of the Ras/MAPK (mitogen-activated protein kinase) pathway. Other disorders with significant phenotypic overlap with NS include neurofibromatosis type 1, LEOPARD (leptigines, electrocardiographic anomalies, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, and deafness) syndrome, Aarskog syndrome, fetal alcohol syndrome, mosaic trisomy 22, and Baraitser-Winter syndrome. Molecular
### TABLE 1 Management Recommendations

<table>
<thead>
<tr>
<th>Clinical Specialty Issue</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetics consultation and follow-up</td>
<td>Decision whether to perform gene testing in individuals with NS phenotype should take into consideration: Positive gene testing can confirm NS diagnosis Negative test results cannot exclude the diagnosis Expected frequency of mutations among patients with definite NS by sequencing the 6 genes known to date is ~60% If sequential molecular testing is determined to be indicated (rather than simultaneous chip based analysis): PTPN11 sequencing should be performed first, because this gene explains the highest number of cases If normal, phenotype should be used to guide the choice of the next gene to sequence If developmental delays are absent or mild, CFC syndrome–like skin and hair findings are present, and/or patient is of normal stature, consider SOS1 sequencing If HCM is present, consider RAL1 sequencing For significant developmental delays or cognitive issues, consider KRAS sequencing For sparse, thin, slow-growing hair, consider SHOC2 sequencing If a variant is found, consider testing the parents to provide accurate recurrence risks</td>
</tr>
<tr>
<td>Cardiovascular issues</td>
<td>All individuals should undergo a cardiac evaluation at the time of diagnosis, including an electrocardiogram and echocardiogram Those found to have cardiac problems should have regular follow-up at intervals determined by the cardiologist; cardiac care should be individualized according to the specific disorder(s) present Some will require treatment such as balloon valvuloplasty or surgery; long-term reevaluation of these patients after treatment is essential (specifically, after successful cardiac surgery, cardiac care should not be discontinued) Individuals without heart disease on their initial evaluation should have cardiac reevaluation every 5 y Adults should not discontinue periodic cardiac evaluations even if their evaluations in childhood or adolescence were normal; unexpected cardiac findings can occur at any point in time</td>
</tr>
<tr>
<td>Growth and endocrine issues</td>
<td>Children should be weighed and measured regularly by the primary care provider, and the data should be plotted on appropriate growth charts (thrice yearly for the first 3 y of life and yearly thereafter) Children with evidence of growth failure (growth deceleration, height less than ~2 SDs, or height inappropriate for genetic background) that cannot be explained by a comorbidity should be monitored more often, have nutrition optimized, have baseline laboratory tests run, and/or be referred to a pediatric endocrinologist Thyroid-function tests and antibodies should be obtained from any child with a goiter and/or symptoms of hypothyroidism (fatigue, constipation, poor growth, etc) Children with evidence of delayed puberty (no breast development in girls by the age of 13 y, no testicular enlargement in boys by 14 y of age) should be referred to a pediatric endocrinologist Therapeutic interventions as indicated (GH for growth failure, thyroid hormone replacement for hypothyroidism, estrogen or testosterone for pubertal delay)</td>
</tr>
<tr>
<td>Renal and genitourinary issues</td>
<td>All individuals should have a kidney ultrasound at the time of diagnosis; a repeat test may be needed depending on initial findings Individuals may be at increased risk of urinary tract infections if a structural abnormality is present Antibiotic prophylaxis may be considered for hydronephrosis and/or recurrent urinary tract infection Orchiopexy should be performed by the age of 1 y if testicles remain undescended at that time</td>
</tr>
<tr>
<td>Gastrointestinal issues</td>
<td>Pediatric gastroenterology/nutrition consultation for feeding difficulties/recurrent vomiting Further testing as indicated (upper-gastrointestinal series, upper endoscopy, pH studies, etc) Therapeutic interventions as indicated (antireflux medications, feeding therapy, feeding tube, surgical consult if malrotation suspected, etc)</td>
</tr>
<tr>
<td>Hematology issues</td>
<td>Screening CBC with differential and prothrombin time/activated partial thromboplastin time at diagnosis and after 6–12 mo of age if initial screen performed in infancy Bleeding symptoms: First tier: CBC with differential count and prothrombin time/activated partial thromboplastin time Second tier (in consultation with hematologist): specific factor activity (factor XI, factor XII, factor IX, factor VIII, von Willebrand factor) and platelet function (bleeding time or platelet aggregation) Surgery: preoperative evaluation (first- and second-tier testing) of bleeding risk; hematology consultation as needed for management of bleeding risk Splenomegaly: CBC with differential count Hepatosplenomegaly: CBC with differential count, liver-function tests Avoidance of aspirin and aspirin-containing medications</td>
</tr>
<tr>
<td>Neurological, cognitive, and behavioral issues</td>
<td>Developmental screening annually Complete neuropsychological testing if screening result is abnormal Evaluations for speech pathology, PT, and OT if delays in speech, gross motor, and fine motor skills, respectively Early-intervention programs beginning in infancy if delays noted Speech therapy for speech and articulation issues, PT and OT for gross and fine motor delays Regular, detailed developmental evaluations throughout childhood Individualized education plan for school-aged children Electroencephalography if referral to neurology if seizures suspected Brain and upper-spine MRI with any neurologic problem (headaches, weakness, numbness, poor balance, etc), cranial size aberration Magnetic resonance angiography (after MRI) if focal/sudden neurologic signs</td>
</tr>
</tbody>
</table>
genetic testing will aid in the differentiation of NS from CFC syndrome, Costello syndrome, LEOPARD syndrome, neurofibromatosis type 1, or Aarskog syndrome. A karyotype will differentiate Turner syndrome from mosaic trisomy 22.

A discussion of scoring systems as algorithms of diagnostic criteria is provided in Supplemental Information.7,18,19

HISTORY OF MOLECULAR GENETIC TESTING AND GENETIC RESEARCH

In 1994, linkage analysis of a large family inheriting NS established definitive linkage to the first NS locus, defined as chromosomal bands 12q22-qter and named NS1.19,20 Genetic heterogeneity was subsequently established.

In 2001, Tartaglia and co-workers21 identified missense mutations in the protein tyrosine phosphatase non–receptor type 11 gene (PTPN11) as the first molecular causes of NS. This discovery was enabled by the observations that PTPN11 resided within the NS1 critical region and that studies with a mouse model of PTPN11 deficiency revealed that its protein product, SHP-2, was critical for the embryologic development of the semilunar cardiac valves.22 Because pulmonary valve stenosis (PVS) is a prominent

TABLE 1

<table>
<thead>
<tr>
<th>Clinical Specialty Issue</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye and ear issues</td>
<td>Detailed eye examination in infancy and/or at diagnosis</td>
</tr>
<tr>
<td></td>
<td>Eye reevaluations as indicated if problems found or at least every 2 y thereafter</td>
</tr>
<tr>
<td></td>
<td>Hearing test in infancy and/or at diagnosis with annual hearing test throughout early childhood</td>
</tr>
<tr>
<td></td>
<td>Attentive management of ear infections to minimize hearing loss</td>
</tr>
<tr>
<td>Orthopedic and dental issues</td>
<td>Annual examination of chest and back, radiography if abnormal</td>
</tr>
<tr>
<td></td>
<td>Careful oral exam at each visit</td>
</tr>
<tr>
<td></td>
<td>Dental referral between the ages of 1 and 2 y and yearly visits thereafter</td>
</tr>
<tr>
<td></td>
<td>Dental radiography as indicated</td>
</tr>
<tr>
<td>Lymphatic issues</td>
<td>Referral of those with peripheral lymphedema to specialty lymphedema clinics</td>
</tr>
<tr>
<td></td>
<td>For more information, contact the National Lymphedema Network (<a href="http://www.lymphnet.org">www.lymphnet.org</a>)</td>
</tr>
<tr>
<td>Anesthesia risk</td>
<td>Individuals with NS should be considered at standard risk for malignant hyperthermia when receiving general anesthesia</td>
</tr>
<tr>
<td></td>
<td>Avoidance of anesthetics associated with malignant hyperthermia in those individuals with NS-like phenotype, a skeletal myopathy, and normal to modestly elevated creatine phosphokinase level and HCM</td>
</tr>
<tr>
<td></td>
<td>Skeletal muscle biopsy should be considered to look for excess muscle spindles (suspect diagnosis of congenital myopathy with excess muscle spindles) in those with NS-like phenotype, a skeletal myopathy, and normal to modestly elevated creatine phosphokinase level and HCM</td>
</tr>
</tbody>
</table>

CBC indicates complete blood count; PT, physical therapy; OT, occupational therapy.

FIGURE 1

A. Patient with NS at (from left to right) 10 days, 6 months, and 2 years of age. B. Patient with NS at (from left to right) 4 months and 1, 2, 5, 9, and 21 years of age.
TABLE 2 Differential Diagnosis: Similarities and Differences Between NS and Other Disorders

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Similarities With NS</th>
<th>Differences From NS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aarskog syndrome</td>
<td>Similarities in NS and Aarskog syndrome are primarily facial and skeletal abnormalities, hypertelorism, Down-slanting palpebral fissures, and short stature. 25</td>
<td>With Aarskog syndrome, no cardiovascular malformations but shawl scrotum is present; this is an X-linked recessive disorder caused by FGFR1 gene mutations.</td>
</tr>
<tr>
<td>Baraitser-Winter syndrome</td>
<td>Features common to both NS and Baraitser-Winter syndrome include hypertelorism, eyelid ptosis, short neck, short stature, relative macrocephaly, PVS, HCM, and ASDs. 9 KRAS or BRAF mutations and rarely SOS1 or MEK1 mutations have been seen in patients with NS and those with CFC syndrome. 16–18</td>
<td>With Baraitser-Winter syndrome, there can be iris coloboma, pachygyria, lissencephaly, bicuspis aortic valve stenosis, and aortic stenosis 17</td>
</tr>
<tr>
<td>CFC syndrome</td>
<td>Common facial, skeletal, and cardiac features in both NS and CFC syndrome include hypertelorism with Down-slanting palpebral fissures, epicanthal folds, and eyelid ptosis, depressed nasal root, short stature, relative macrocephaly, PVS, HCM, and ASDs. 9 KRAS or BRAF mutations and rarely SOS1 or MEK1 mutations have been seen in patients with NS and those with CFC syndrome. 16–18</td>
<td>With CFC syndrome, coarser facial features, severe feeding problems, follicular hyperkeratosis, sparse eyebrows and eyelashes, ichthyosis, and ulcerative ophryogenes; majority have moderate retardation; may be caused by MEK1 or MEK2 mutations.</td>
</tr>
<tr>
<td>Costello syndrome</td>
<td>Many features common to both Costello syndrome and NS include hypertelorism, Down-slanting palpebral fissures, epicanthal folds, PVS, HCM, pectus deformity, and Chiari I malformation. 26,27</td>
<td>With Costello syndrome, coarse facial features, wide nasal bridge, loose skin, increased pigmentation with age, deep palmar and plantar creases, papilloma of the face or periorbital region, premature aging and hair loss, multifocal atrial tachycardia, moderate mental retardation, and ulnar deviation of the wrist and fingers 14, caused by HRAS mutations</td>
</tr>
<tr>
<td>Fetal alcohol syndrome</td>
<td>Common features to both NS and fetal alcohol syndrome include growth delay, developmental delay, hypertelorism, epicanthal folds, PVS, and ASD. 28,29</td>
<td>With fetal alcohol syndrome, born small for gestational age, microcephaly, cleft palate, small palpebral fissures, smooth philtrum, thin-lip vermilion, and a wider range of cardiac defects including ventricular septal defect, endocardial cushion defect, conotruncal abnormalities, and coarctation of the aorta</td>
</tr>
<tr>
<td>LEOPARD syndrome</td>
<td>Common features to LEOPARD syndrome and NS include hypertelorism, PVS, HCM, and short stature; caused by PTPN11, RAF1, or BRAF gene mutations</td>
<td>With LEOPARD syndrome: Sensoneural deafness, multiple skin lentigines, pigmented lesions, conduction abnormalities, 30% have mental retardation</td>
</tr>
<tr>
<td>Mosaic trisomy 22</td>
<td>Similar facial features include hypertelorism and ptosis. 30</td>
<td>In mosaic trisomy 22: No congenital heart defects are seen, 31 and cognitive development more impaired.</td>
</tr>
<tr>
<td>Neurofibromatosis type 1</td>
<td>Some people with neurofibromatosis type 1 gene mutations have NS-like facial features and PVS 32</td>
<td>With neurofibromatosis type 1, multiple café au lait, axillary, and inguinal freckling, cutaneous neurofibroma, and iris Lisch nodules</td>
</tr>
<tr>
<td>Turner syndrome</td>
<td>Girls with NS and Turner syndrome can have short stature, eyelid ptosis, increased internipple distance, webbed neck, and pituitary malformations. 8</td>
<td>Cardiac features are typically left-sided in Turner syndrome but right-sided in NS; coarctation of the aorta and/or bicuspis aortic valve are more characteristic of Turner syndrome; girls have gonadal dysgenesis in Turner syndrome; normal fertility in girls with NS. Turner syndrome is attributable to loss of 1 sex chromosome.</td>
</tr>
</tbody>
</table>

Feature of NS, these investigators reasoned that PTPN11 was a leading positional candidate gene in NS1. In addition, Tartaglia and co-workers recognized that SHP-2, a protein tyrosine phosphatase with largely positive regulatory roles in Ras/MAPK signaling, participated in signaling downstream from several ligand-receptor complexes with possible relevance to the pleomorphic abnormalities observed in NS (e.g., fibroblast growth factor for bone development, growth hormone [GH] and insulin-like growth factor for somatic growth). The reasoning of these investigators proved correct, because they observed PTPN11 missense mutations in 2 medium-sized families inheriting NS in a pattern consistent with linkage to NS7 and then additional mutations in approximately half of a small number of sporadic cases or small families with NS. Subsequent molecular discovery indicated that other genetic syndromes that resembled NS phenotypically, Costello and CFC syndromes, proved not to be allelic. 23–26 LEOPARD syndrome, on the other hand, proved to be allelic with PTPN11; mutations account for ~90% of cases, and specific mutations, particularly Y259C and T468M, are prevalent only in LEOPARD syndrome. 27,28 Other Ras/MAPK genes were then considered as candidate genes that might be mutated in patients with NS that is not explained by PTPN11. HRAS mutations were shown to cause Costello syndrome, and 4 Ras/MAPK genes (KRAS, BRAF, MEK1, and MEK2) were mutated in CFC syn-
By using this candidate gene approach, 6 additional Ras/MAPK candidate genes were identified from 2006 to the present: \textit{KRAS}, \textit{NRAS}, \textit{SOS1}, \textit{RAF1}, \textit{BRAF}, and \textit{SHOC2}.12,30–35

**Genetic Testing for NS**

The currently available commercial tests use different technologies (dideoxynucleotide sequencing, denaturing high-performance liquid chromatography, and oligonucleotide-based microarray sequencing) that fundamentally are based on the presence of missense or small insertions/deletions in the coding regions and flanking intron boundaries of genes that cause NS. Although gross chromosomal abnormalities (interstitial deletions, duplications, and balanced translocations) have rarely been identified in patients with phenotypes that closely resembled (or were) NS, routine karyotyping or copy-number analysis is not recommended at this time for typical NS cases. It may be considered for atypical cases or when there is particularly severe neurocognitive involvement.

**Postnatal Mutation Testing for NS**

Table 3 summarizes the studies that comprised \(\geq 20\) subjects of postnatal mutation testing for NS since 2001. There are important limitations in the interpretation of these data, including the heterogeneity in NS diagnostic clinical criteria, the occurrence of phenotyping at different ages, and a case-mix sensitivity (the rate of \textit{PTPN11} mutations among familial cases of NS is nearly double that among sporadic cases). Mutations in the 7 genes identified for NS to date account for 61% of postnatal cases. There is currently no information concerning the number of cases, if any, that harbor more than 1 mutation for NS because all studies took a sequential genotyping approach. Because 1 center recently introduced the use of microarray-based sequencing in which all relevant genes are analyzed in parallel, it will be of interest to discover whether multiple hits are observed in some subset of patients with NS.

A suggested algorithm for individual genotyping is shown in Table 1. The rationale for this algorithm and a discussion of prenatal mutation testing in NS is provided in Supplemental Information.

**GENOTYPE/PHENOTYPE CORRELATIONS**

Among the mutated genes that account for NS, many different genotype/phenotype correlations have been made. No phenotypic features are found exclusively among 1 genotype, probably because of genetic and epigenetic factors that influence both penetrance and expressivity. Table 4 summarizes some genotype/phenotype correlations that may be useful for clinicians, but note that there are no phenotypic features exclusive to a specific genotype. There are, however, significant differences in the risk of various NS manifestations based on the causative gene.

**TABLE 3** Summary of Postnatal Mutation Testing for NS

<table>
<thead>
<tr>
<th>Gene</th>
<th>Total No. of Subjects</th>
<th>No. of Studies</th>
<th>Mutation-Positive Patients, n (% of Study Cohort)</th>
<th>% of All Cases Genotyped</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>\textit{PTPN11}</td>
<td>972,20,26,30–33,45,51–53,139</td>
<td>877</td>
<td>13</td>
<td>359 (40.9)</td>
<td>40.9*</td>
</tr>
<tr>
<td>\textit{KRAS}</td>
<td>972,20,26,30–33,45,51–53,139</td>
<td>616</td>
<td>6</td>
<td>15 (2.4)</td>
<td>1.4</td>
</tr>
<tr>
<td>\textit{SOS1}</td>
<td>972,20,26,30–33,45,51–53,139</td>
<td>311</td>
<td>5</td>
<td>60 (19.3)</td>
<td>11.1</td>
</tr>
<tr>
<td>\textit{RAF1}</td>
<td>972,20,26,30–33,45,51–53,139</td>
<td>304</td>
<td>4</td>
<td>31 (10.2)</td>
<td>4.7</td>
</tr>
<tr>
<td>\textit{BRAF}</td>
<td>972,20,26,30–33,45,51–53,139</td>
<td>334</td>
<td>3</td>
<td>6 (1.8)</td>
<td>0.8</td>
</tr>
<tr>
<td>\textit{SHOC2}</td>
<td>30–33,45,51–53,139</td>
<td>96</td>
<td>1</td>
<td>4 (4.2)</td>
<td>1.7</td>
</tr>
<tr>
<td>\textit{NRAS}</td>
<td>972,20,26,30–33,45,51–53,139</td>
<td>733</td>
<td>1</td>
<td>4 (0.5)</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>*</td>
<td>32</td>
<td>*</td>
<td>61</td>
<td>—</td>
</tr>
</tbody>
</table>

*Total values were not calculated for columns 2 and 4 because of overlap of patients (ie, mutation-negative patients were often tested again in separate studies for subsequent mutations).
Patients with the *SHOC2* S2G mutation have a distinctive phenotype, initially termed Noonan-like syndrome, with loose anagen hair. In addition to the hair findings, the phenotype may include mitral valve and cardiac septal defects, GH deficiency, ectodermal abnormalities with darkly pigmented ichthyotic skin, hypernasal voice, and developmental issues with hyperactivity.

In a study of 45 patients with NS, both bleeding diathesis and juvenile myelomonocytic leukemia were found exclusively in patients with specific *PTPN11* mutations. Familial cases of NS are more likely than sporadic cases to be caused by a *PTPN11* mutation. NS attributable to *KRAS* mutations seems to confer a more severe phenotype with more significant learning issues and developmental delays.

**CARDIOVASCULAR ISSUES**

More than 80% of patients with NS have an abnormality of the cardiovascular system. PVS is the most common. The valve may be dysplastic in 25% to 35% of those with PVS and is often associated with an ASD. Isolated ASDs and partial atroventricular canal defects are also relatively common. A broad spectrum of cardiac abnormalities has been reported, as noted in Table 5. Approximately 50% of patients with NS have an unusual electrocardiographic pattern characterized by left-axis deviation, an abnormal R/S ratio over the left precordial leads, and an abnormal Q wave. Many patients have mild PVS that requires only periodic reevaluation. If the PVS is or becomes clinically significant, initial treatment is usually pulmonary balloon valvuloplasty, but it may be unsuccessful if the valve is dysplastic. With severe dysplasia, a pulmonary valvectomy or pulmonary homograft may be needed in childhood. The other cardiac defects can be treated in the standard ways.

HCM is present in ~20% of patients with NS overall but is particularly frequent with *RAF1* mutations, and it is variable in severity and natural history. In some infants with HCM the condition resolves, whereas in others it becomes rapidly progressive and may have a fatal outcome. Others develop HCM after infancy. The course may be stable or progressive, or it may improve. Management is similar to that for any patient with HCM and may include the use of β-blocker medications or surgical myomectomy to reduce outflow obstruction.

It is important for adults with NS to have lifetime cardiac follow-up. Left-sided obstructive lesions may develop in adulthood. Pulmonary valve insufficiency and right ventricular dysfunction are potential problems after earlier pulmonary valve surgery. Cardiac arrhythmias have been rare in the limited reports available about long-term follow-up of adults.

**GROWTH AND ENDOCRINE ISSUES**

**Growth**

Approximately 50% to 70% of individuals with NS have short stature. Birth weight and length are typically normal, but there is a sub-
sequent deceleration of height and weight to the third centile or less. The mean delay of bone age is ~2 years.\textsuperscript{7,72} NS-specific growth charts have been published.\textsuperscript{72,73}

Mean adult heights of European individuals with NS have been reported for women as ~153.0 cm and for men as 162.5 and 169.8 cm.\textsuperscript{6,72} The mean adult height of North American individuals is less than the third centile in 54.5% of women (<151 cm) and 38% of men (<163.2 cm).\textsuperscript{74,77} A higher prevalence of short stature has been found in \textit{PTPN11} mutation-positive subjects than in mutation-negative subjects, and a lower prevalence of short stature has been described for those with \textit{SOS1}-associated NS.\textsuperscript{50,51}

Reports of GH-secretory dynamics have been inconsistent and are likely a reflection of the genotypic heterogeneity of NS. There have been reports of GH deficiency (45% \(n = 150\)\textsuperscript{86} 37% \(n = 27\)\textsuperscript{72}), neurosecretory dysfunction,\textsuperscript{76–80} and completely normal GH secretion.\textsuperscript{81,82} Insulin-like growth factor 1 (IGF1) has been described for those with \textit{PTPN11}-associated NS.\textsuperscript{50,51}

Mean adult heights of European individuals with NS have been reported for women as ~153.0 cm and for men as 162.5 and 169.8 cm.\textsuperscript{6,72} The mean adult height of North American individuals is less than the third centile in 54.5% of women (<151 cm) and 38% of men (<163.2 cm).\textsuperscript{74,77} A higher prevalence of short stature has been found in \textit{PTPN11} mutation-positive subjects than in mutation-negative subjects, and a lower prevalence of short stature has been described for those with \textit{SOS1}-associated NS.\textsuperscript{50,51}

Until recently, most experience with GH in NS has been reported in studies that involved small numbers of patients with varied enrollment ages, treatment durations, doses, and responses. These studies resulted in improved growth velocity without significant adverse effects.\textsuperscript{78–80,84–86} Although most studies have excluded patients with HCM, left ventricular wall thickness remained normal when prospectively measured in patients with NS on GH.\textsuperscript{76–78} In addition, among the combined 889 patients from 6 articles that reported adult-height outcomes in patients with NS on GH,\textsuperscript{84,88–92} there were only 5 reported cardiac events (2 mild progressions of PVS, 1 HCM, 1 increased biventricular hypertrophy, and 1 cardiac decompensation).

The efficacy of GH in NS can be assessed by considering adult-height data (Table 6).\textsuperscript{84,88–91} Although different parameters were reported in these studies (ie, median versus mean values, height SD scores based on population standards versus the NS-specific standards, varied doses, etc), it seems that improved outcomes (\(\Delta\) height SD score: 1.3–1.7; mean height gain: 9.5–13 cm for boys and 9.0–9.8 cm for girls\textsuperscript{89,90,95}) occur with earlier initiation and longer duration of GH therapy, as has been demonstrated for other conditions such as Turner syndrome.\textsuperscript{93,94}

Initial short-term data have suggested that \textit{PTPN11}-positive patients responded “less efficiently” to GH than did the \textit{PTPN11}-negative patients.\textsuperscript{48} In contrast, longer-term data from comparisons of adult heights for those treated with GH among those who were \textit{PTPN11} mutation-positive with those who were mutation-negative revealed no difference in outcome.\textsuperscript{90} Additional studies may clarify the role of the different RAS/MAPK pathway aberrations in growth and GH responsiveness.

### Other Endocrine and Autoimmune Issues

Puberty is typically, but not universally, delayed for both boys and girls with NS and is characterized by a diminished pubertal growth spurt.\textsuperscript{72} The mean age of pubertal onset is 13.5 to 14.5 years in boys and 13 to 14 years in girls. Puberty may progress with a rapid tempo (<2 years).\textsuperscript{92} Pubertal induction may be instituted (with careful consideration of timing for optimal height potential) for no secondary sexual characteristics in boys at 14 years (testosterone induction) and girls at 13 years (estrogen induction).

Thyroid antibodies are commonly found, but hypothyroidism is likely no more common in those with NS than in the general population.\textsuperscript{7,95–97} There have been case reports of the occurrence of other autoimmune conditions, such as systemic lupus erythematosus and celiac disease, but their frequency is unknown.\textsuperscript{98–100}

### TABLE 6 Baseline and Treatment Growth Data From Studies That Reported Adult-Height Outcomes in Individuals With NS Treated With GH

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patients, n (n Female)</th>
<th>Baseline Age, y</th>
<th>Baseline SDS\textsuperscript{a}</th>
<th>GH Dose, mg/kg per wk</th>
<th>Duration Therapy, y</th>
<th>Delta Height SDS</th>
<th>Height Gain</th>
</tr>
</thead>
<tbody>
<tr>
<td>88</td>
<td>4 (4)</td>
<td>13.5</td>
<td>(−0.6)</td>
<td>0.19 for 1 y, then 0.31</td>
<td>3.5</td>
<td>(0.48)</td>
<td>NA</td>
</tr>
<tr>
<td>84</td>
<td>10 (4)</td>
<td>12</td>
<td>−3.1 (−0.7)</td>
<td>0.30</td>
<td>3.1</td>
<td>3.1 cm</td>
<td></td>
</tr>
<tr>
<td>89</td>
<td>18 (11)</td>
<td>8.6 (boys), 7.7 (girls)</td>
<td>−2.9 (−0.3)</td>
<td>0.23 (n = 10), 0.46 (n = 15) for 2 y, then dose titration\textsuperscript{b}</td>
<td>7.5</td>
<td>1.7</td>
<td>13 cm (boys), 9.8 cm (girls)</td>
</tr>
<tr>
<td>91</td>
<td>24 (NA)</td>
<td>10.2 (median)</td>
<td>−3.24 (median)</td>
<td>0.24 (median [range: 0.17–0.77])</td>
<td>7.59 (median)</td>
<td>0.61 (0.97)</td>
<td>NA</td>
</tr>
<tr>
<td>90</td>
<td>29 (8)</td>
<td>11</td>
<td>−2.8 (0.0)</td>
<td>0.35</td>
<td>6.4 (median)</td>
<td>1.13 (1.3)</td>
<td>9.5 cm (boys), 9.0 cm (girls)</td>
</tr>
<tr>
<td>92</td>
<td>65 (30)</td>
<td>11.6</td>
<td>−3.5</td>
<td>0.33</td>
<td>5.6</td>
<td>1.4</td>
<td>10.9 cm (boys), 9.2 cm (girls)</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Height SDS is reported according to population standards and/or (NS standards).

\textsuperscript{b}Estimated mean: 0.35 mg/kg per week.
RENAL AND GENITOURINARY ISSUES
Renal anomalies occur in 10% to 11% of those with NS and are usually of little significance. Solitary kidney, renal pelvis dilatation, and duplicated collecting system have been reported. Cryptorchidism occurs in up to 80% of boys, and surgical orchiopexy is required. Recent evidence suggests serotoli cell dysfunction rather than cryptorchidism as the etiology of male gonadal dysfunction. Fertility does not seem to be affected in women.

HEMATOLOGY AND ONCOLOGY ISSUES
Disordered bleeding has been reported for 30% to 65% of individuals with NS. Although the symptoms are often mild, such as excessive bruising, epistaxis, or menorrhagia, bleeding with surgical procedures can be significant. A number of coagulation-factor deficiencies (isolated and combined), thrombocytopenia, and platelet dysfunction have been described. Elevation of the activated partial thromboplastin time is frequent. Approximately 25% of individuals with NS have partial factor XI deficiency. The bleeding symptoms do not correlate well with the degree of deficiency. A number of other coagulation factors can be depressed, and low factor XII and factor VIII activity are the next most frequent deficiencies, which is a common bleeding disorder in the general population; although both low factor VIII and von Willebrand factor have been reported in NS, an accurate estimate of the prevalence of von Willebrand disease in patients with NS has not yet been determined. Less commonly, factor IX and factor II have also been reported to be deficient in patients with NS and can contribute to bleeding risk.

Both thrombocytopenia and platelet dysfunction have been described in patients with NS. The etiology of the thrombocytopenia is probably multifactorial and can be associated with a defect in platelet production caused by a decrease in megakaryocytes. Splenomegaly may also cause mild-to-moderate thrombocytopenia and is found by ultrasound in up to 52% of patients with NS. Splenomegaly may be isolated or associated with hepatomegaly. In some patients, hepatosplenomegaly or splenomegaly may be caused by NS/myeloproliferative disorder (MPD).

NS/MPD is a condition seen in infants with NS that is characterized by leukocytosis with monocytosis, thrombocytopenia, and hepatosplenomegaly. Although the clinical picture of NS/MPD resembles that of juvenile myelomono-cytic leukemia, infants with NS/MPD seem to have a favorable prognosis. Although some infants with NS/MPD have been reported to develop aggressive leukemia, the majority with this condition present in the first few months of life and will remain stable or improve by 1 year of age without specific therapy.

Despite the role of somatic PTPN11 and KRAS mutations in the development of malignancies, the incidence of cancer in older children and adults with NS has not been shown to be increased over that of the general population. However, additional studies are needed to accurately assess the risk of malignancy in individuals with NS.

NEUROLOGIC, COGNITIVE, AND BEHAVIORAL ISSUES
The neurologic, cognitive, and behavioral aspects of individuals with NS are poorly understood and extremely variable. There is an increased incidence of cognitive issues and learning disabilities, an increased incidence of brain abnormalities, and a wide array of other neurologic problems. In a study of 151 subjects with NS, 76% had feeding difficulties, 94% had ocular problems, 50% had hypermobility of joints/hypotonia, 13% had recurrent seizures, 3% had hearing loss, and 3% had peripheral neuropathy. There was also a general delay in the mean age of motor milestones; sitting alone occurred at 10 months, walking occurred at 21 months, and speaking 2-word sentences occurred at 31 months. Another study revealed that 84% had some type of neurologic problem.

Structural malformations and deformations of the central nervous system and spinal cord are found at relatively low frequency. The most common defects are Arnold-Chiari malformation type I and hydrocephalus. The mean head circumference is at the 50th percentile; however, some individuals with NS can be microcephalic or macrocephalic.

Most people with NS have normal intelligence, but 10% to 40% require special education. Even among those of normal intelligence, IQ has been shown to be 10 points less than unaffected family members or 1 SD below that of the general population. The observed heterogeneity in cognitive abilities in syndromes of the Ras/MAPK signaling cascade including NS can be at least partially ascribed to the individual affected genes and the type of mutation. For example, SOS1 mutations and specific PTPN11 mutations have been associated with no or mild cognitive delays.

Children with NS have a higher rate of clumsiness, poor coordination, stubbornness, and irritability. Body-image problems and poor self-esteem, depression, and social inadequacy have been noted to occur in adults with
NS. Limited data are available on the psychological and psychiatric characteristics of patients with NS. Psychiatric problems are rarely found, and qualitative data in a study of 112 adults with NS revealed their reporting of an inability to fit in but an overall good or satisfactory quality of life. In addition, the majority of adults with NS finished high school and had paying jobs.

**GASTROINTESTINAL AND FEEDING ISSUES**

Most infants (75%) with NS have feeding difficulties; poor suck with prolonged feeding time (15%), very poor suck and slow feeding with recurrent vomiting (38%), and severe feeding problems that require tube-feeding for ≥2 weeks (24%) have been described. Investigation of some children with poor feeding has revealed immaturity of gut motility and delayed gastrointestinal motor development. Gastroesophageal reflux is common, and there have been a few reports of malrotation. Typically, the period of failure to thrive is self-limited, although poor weight gain may persist for up to 18 months.

**ORAL AND DENTAL ISSUES**

Oral findings in patients with NS include a high arched palate (55%–100%), dental malocclusion (50%–67%), articulation difficulties (72%), and micrognathia (33%–43%). Some individuals with NS develop mandibular cysts, which can mimic cherubism. The pathology of these lesions in individuals with NS is characterized by multinucleated giant cells within a fibrous stroma and is indistinguishable from cherubism. These 2 conditions, however, are genetically distinct; SH3BP2 gene mutations are found in individuals with cherubism, whereas PTPN11 and SOST mutations are found in patients with NS with giant cell lesions.

**LYMPHATIC ISSUES**

NS is associated with a generalized disorder of lymphatic development, which has manifestations in fetal life through adulthood. The overall incidence of lymphatic manifestations in all age groups of those with NS is unknown, but it is estimated to be ~20%. Peripheral lymphedema, the most common lymphatic manifestation, is seen most frequently in young infants. It typically resolves in the first few years. Adolescents and adults can develop peripheral lymphedema. Other types of lymphatic involvement that have been described in patients with NS include hydrops, chylous pleural effusions, chylothorax, pulmonary lymphangiectasis, intestinal lymphangiectasia, hypoplastic leg lymphatics, anomalous lymphatic vessels in the thoracic cage and aplasia or absence of the thoracic duct, hypoplastic inguinal and iliac lymphatic vessels, and testicular lymphangiectasia. Management of these conditions can be difficult.

Other types of lymphatic involvement have been reported in patients with NS, such as hydrocele, chylothorax, and pulmonary lymphangiectasis. Peripheral lymphedema is the most common lymphatic manifestation, and it typically resolves in the first few years. Adolescents and adults can develop peripheral lymphedema. Other types of lymphatic involvement that have been described in patients with NS include hydrops, chylous pleural effusions, chylothorax, pulmonary lymphangiectasis, intestinal lymphangiectasia, hypoplastic leg lymphatics, anomalous lymphatic vessels in the thoracic cage and aplasia or absence of the thoracic duct, hypoplastic inguinal and iliac lymphatic vessels, and testicular lymphangiectasia. Management of these conditions can be difficult.

**TABLE 7 Support Organizations for NS**

<table>
<thead>
<tr>
<th>Organization</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noonan Syndrome Support Group</td>
<td>Internet: <a href="http://www.noonansyndrome.org">www.noonansyndrome.org</a>; telephone: 888-686-2224 or 410-374-5245; address: PO Box 145, Upperco, MD 21155</td>
</tr>
<tr>
<td>Magic Foundation</td>
<td>Internet: <a href="http://www.magicfoundation.org">www.magicfoundation.org</a>; telephone: 800-362-4423 or 708-383-0808; Address: 6645 W North Ave, Oak Park, IL 60302</td>
</tr>
<tr>
<td>NORD: National Organization for Rare Disorders</td>
<td>Internet: <a href="http://www.rarediseases.org">www.rarediseases.org</a>; telephone: 203-744-0100; address: 55 Kenosia Ave, PO Box 1968, Danbury, CT 06813-1968</td>
</tr>
<tr>
<td>Human Growth Foundation</td>
<td>Internet: <a href="http://www.hgfound.org">www.hgfound.org</a>; telephone: 800-451-6434; address: 997 Glen Cove Ave, Suite 5, Glen Head, NY 11545</td>
</tr>
<tr>
<td>BDF Newlife</td>
<td>Internet: <a href="http://www.bdfnewlife.co.uk">www.bdfnewlife.co.uk</a>; telephone: 01543 468888; address: Hemlock Business Park, Hemlock Way, Cannock, Staffordshire WS11 7DF, United Kingdom</td>
</tr>
</tbody>
</table>

**ACKNOWLEDGMENTS**

This article was developed through a conference organized by the Noonan Syndrome Support Group. The funding for the conference was provided by an independent medical education grant from Novo Nordisk, Inc to the Noonan Syndrome Support Group. Representatives from Novo Nordisk, Inc did not participate in any scientific deliberations, did not contribute to the content of this report, and did not review or comment on this report before publication.

We thank Dr Mignon Loh for helpful discussion about NS/MPD.
REFERENCES

33. Bertola DR, Pereira AC, Albano LM, De Oliveira PS, Kim CA, Krieger JE. PTPN11 gene...
analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype. Genet Test. 2006;10(3):186–191


65. Noordam C, van der Burgt I, Sweep CG, Delemarre-van de Waal HA, Sengers RC, Otten BJ. Growth hormone (GH) secretion in children with Noonan syndrome: frequently abnormal without consequences...
for growth or response to GH treatment. *Clin Endocrinol (Oxf).* 2001;54(1):53–59


(Continued from first page)

Copyright © 2010 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: Dr Romano is a consultant to both Genentech, Inc and Novo Nordisk, Inc and also participates on the speaker’s bureau of both companies; Dr Dahlgren received grants in 2008 from Novo Nordisk, Inc for genetic analysis of individuals with NS; Dr Gelb currently has SOS1, RAF1, and SHOC2 gene patents pending and receives royalties for PTPN11 mutation testing from GeneDx, Correlegran, Prevention Genetics, Baylor College of Medicine, and Harvard Partners; and Dr Roberts currently has an SOS1 gene patent pending. The other authors have indicated they have no financial relationships relevant to this article to disclose.
Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines
Alicia A. Romano, Judith E. Allanson, Jovanna Dahlgren, Bruce D. Gelb, Bryan Hall, Mary Ella Pierpont, Amy E. Roberts, Wanda Robinson, Clifford M. Takemoto and Jacqueline A. Noonan

Pediatrics 2010;126;746; originally published online September 27, 2010; DOI: 10.1542/peds.2009-3207

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/126/4/746.full.html

Supplementary Material
Supplementary material can be found at:
http://pediatrics.aappublications.org/content/suppl/2010/09/15/peds.2009-3207.DC1.html

References
This article cites 137 articles, 20 of which can be accessed free at:
http://pediatrics.aappublications.org/content/126/4/746.full.html#ref-list-1

Citations
This article has been cited by 21 HighWire-hosted articles:
http://pediatrics.aappublications.org/content/126/4/746.full.html#related-urls

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Genetics
http://pediatrics.aappublications.org/cgi/collection/genetics_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://pediatrics.aappublications.org/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
http://pediatrics.aappublications.org/site/misc/reprints.xhtml

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2010 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.
Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines

Alicia A. Romano, Judith E. Allanson, Jovanna Dahlgren, Bruce D. Gelb, Bryan Hall, Mary Ella Pierpont, Amy E. Roberts, Wanda Robinson, Clifford M. Takemoto and Jacqueline A. Noonan

Pediatrics 2010;126;746; originally published online September 27, 2010;
DOI: 10.1542/peds.2009-3207

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/126/4/746.full.html